1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
CareDx, Inc

CareDx, Inc

CDNA
CareDx, IncUS flagNASDAQ Global Market
67.08
USD
+3.08
- -
3.47BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
3
4.7
2.37
2.46
2.07
2.15
3.01
4.13
5.67
6.03
5.21
6.32
7.13
8.88
Basic EPS, GAAP
-0.48
0.13
-1.16
-2.39
-2.38
-1.31
-0.52
-0.4
-0.59
-1.44
-3.54
1
-0.4
2.15
Free Cash Flow per Basic Share
-0.09
-0.7
-0.92
-1.03
-0.62
-0.32
-0.09
0.65
-0.5
-0.53
-0.36
0.72
0.78
1.74
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-14.34
3.5
2.48
0.92
-0.21
2.32
2.33
5.62
8.8
8.05
5.07
6.91
5.95
8.27
Tangible Book Value per Share
-14.34
1.92
0.91
-1.29
-1.78
1.22
0.7
4.24
7.16
6.54
3.4
5.48
4.53
7.21
Basic Weighted Avg Shares
7
6
12
16
23
36
42
46
52
53
54
53
53
52
Sales/Revenue/Turnover
22
27
28
41
48
77
127
192
296
322
280
334
380
458
Operating Margin (%)
-3.88
0.04
-42.84
-60.96
-37.94
-20.35
-19.31
-9.22
-10.03
-24
-38.19
-16.64
-6.6
-0.92
Depreciation Expense
1
1
1
3
4
4
7
10
12
16
20
20
20
20
Net Income, GAAP
-4
1
-14
-39
-55
-47
-22
-19
-31
-77
-190
53
-21
111
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.59
- -
3.63
Profit Margin (%)
-16.03
2.86
-48.7
-97.14
-114.79
-61.06
-17.29
-9.74
-10.34
-23.81
-67.88
15.74
-5.62
24.23
Working Capital
1
29
24
-14
-16
62
37
204
356
312
236
262
167
336
LT Debt
11
5
13
1
18
- -
2
16
17
33
28
22
20
13
Total Equity
-151
41
29
20
-6
96
99
278
466
431
261
378
303
426
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-15.72
- -
-1.02
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
14.96
- -
27.71
Return on Common Equity (%)
- -
- -
-38.72
-161.18
- -
- -
-22.54
-9.94
-8.25
-17.09
-54.98
16.43
-6.27
29.49

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
7
7
6
LT Borrowings
- -
- -
- -
LT Finance Leases
20
18
13
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
51
51
51
Market Capitalization
959
890
1,467

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
257
269
429
Cash, Cash Equivalents & STI
177
187
374
Accounts Receivable, Net
43
45
34
Inventories
27
26
7
Total Current Liabilities
90
79
94
Payables & Accruals
37
38
38
ST Debt
7
7
6
Deferred Revenue
5
6
6

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-164.48%
9.16%
-19.91%
Free Cash Flow
-141.5%
-99.53%
8.7%
Net Income, GAAP
23.88%
18.76%
-140.64%
Sales/Revenue/Turnover
32.17%
16.55%
13.79%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
72
92
83
87
334
2025
85
87
100
108
380
2026
118
132
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.38
-0.09
-0.2
1.44
1
2025
-0.19
-0.16
0.03
-0.08
-0.4
2026
0.05
2.15
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
John Walter Hanna Jr.
Full Time Employees
763
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Address
8000 Marina Boulevard Brisbane CA United States of America 94005
IPO Date
Jul 17, 2014
CIK
0001217234
Website
caredx.com
Similar Companies
SeqLL Inc. (SQLLW)
King International Investment Limited (0928.HK)
InVitro International (IVRO)
Many Bright Ideas Technologies Inc. (MBGNF)
Dr. Lalchandani Labs Ltd. (DLCL.BO)
Global WholeHealth Partners Corporation (GWHP)
Business
CareDx, Inc. CareDx, Inc. (Nasdaq: CDNA) operates as a leading precision medicine company focused on the discovery, development, and commercialization of diagnostic solutions, testing services, products, and digital healthcare tools for transplant patients and caregivers along the pre- and post-transplant journey. The company offers core products and services including AlloSure Kidney, AlloSure Heart, AlloSure Lung, and AlloMap Heart gene expression profiling tests, which utilize donor-derived cell-free DNA (dd-cfDNA) for noninvasive surveillance to detect organ injury and rejection in kidney, heart, and lung transplant recipients; AlloSeq and QTYPE for superior HLA typing with hybrid capture technology; HeartCare, combining AlloMap Heart and AlloSure Heart; digital solutions such as the AlloCare mobile app for patient medication management, health tracking, and care coordination, and transplant administration software like Ottr acquired via TransChart in 2021; transplant lab products for matching; and pharma services to accelerate biopharma clinical development. Founded in 1998 and headquartered in Brisbane, California, with principal operations in South San Francisco, California; Omaha, Nebraska; Fremantle, Australia; and Stockholm, Sweden, CareDx primarily generates revenue from the United States while serving over 150 U.S. transplant centers and more than 30,000 patients. Recent developments include the launch of AlloSure Plus (formerly AlloView), an AI-driven diagnostic platform integrating dd-cfDNA with clinical methods for improved rejection prediction; new IVD products and IVDR certification for AlloSeq Tx and QTYPE announced at the 2025 American Society of Histocompatibility & Immunogenetics Annual Meeting; the launch of HistoMap Kidney, a tissue-based gene expression assay to characterize rejection phenotypes, planned for early 2026; partnerships such as with Leidos to transform the Organ Procurement and Transplantation Network, TC BioPharm for AML therapy trials using AlloCell testing, and agreements with Illumina and Cibiltech; installation of the EPIC environment and customer pilots; and strong Q3 2025 financial results with 21% revenue growth, 30% increase in patient and digital solutions revenue, and improved profitability.

Company News

Company News APIChatGPT

  • gurufocus.com

    CareDx Inc (CDNA) Shares Fall 4.0% -- GF Value Says Still Overvalued

  • businesswire.com

    CareDx to Report Third Quarter 2026 Financial Results on October 29, 2026

  • defenseworld.net

    Critical Contrast: CollPlant Biotechnologies (NASDAQ:CLGN) & CareDx (NASDAQ:CDNA)

  • zacks.com

    CareDx (CDNA) Stock Jumps 13.0%: Will It Continue to Soar?

  • benzinga.com

    Medicare Lab Fee Changes Impact BillionToOne, CareDx Differently

  • zacks.com

    5 Top-Ranked High-Efficiency Stocks With Strong Profit Potential

  • defenseworld.net

    CareDx (NASDAQ:CDNA) Hits New 1-Year High – Time to Buy?

  • zacks.com

    4 Healthcare Stocks to Play Safe as Fed Gears Up for Rate Hike

  • zacks.com

    Oil Surge Continues on Escalating Middle East Crisis: 4 Defensive Picks

  • zacks.com

    Are Medical Stocks Lagging CareDx (CDNA) This Year?

  • defenseworld.net

    Canada Pension Plan Investment Board Takes Position in CareDx, Inc. $CDNA

  • zacks.com

    CareDx (CDNA) is a Great Momentum Stock: Should You Buy?

  • defenseworld.net

    Bamco Inc. NY Makes New $55.21 Million Investment in CareDx, Inc. $CDNA

  • zacks.com

    Zacks Industry Outlook CareDx, BrightSpring and PACS

  • zacks.com

    3 Medical Service Stocks Resilient Amid Persistent Workforce Shortage

  • gurufocus.com

    Ron Baron Trims CareDx Inc (CDNA) Stake -- Shares Trade 86% Above GF Value

  • zacks.com

    5 Top-Ranked High-Efficiency Stocks Poised for Stronger Returns

  • businesswire.com

    CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • businesswire.com

    CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • fool.com

    Why CareDx Stock Jumped Today